NR4A1 and breast carcinoma: In our computational drug repositioning analysis, our method predicted that tamoxifen (the second ranked candidate, see Table 2), an FDA-approved estrogen receptor modulator for the treatment of hormone-receptor-positive breast cancer patients, could serve as a potential drug target for Alzheimer’s disease.